Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Other Operating Expenses (2019 - 2025)

Karyopharm Therapeutics filings provide 7 years of Other Operating Expenses readings, the most recent being $1.5 million for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 11.5% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.9 million, a 0.97% decrease, with the full-year FY2025 number at $5.9 million, down 0.97% from a year prior.
  • Other Operating Expenses hit $1.5 million in Q4 2025 for Karyopharm Therapeutics, down from $2.1 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $2.1 million in Q3 2025 to a low of -$73.8 million in Q1 2021.
  • Median Other Operating Expenses over the past 5 years was $1.3 million (2024), compared with a mean of -$2.5 million.
  • Biggest five-year swings in Other Operating Expenses: plummeted 9106.96% in 2021 and later soared 151.75% in 2022.
  • Karyopharm Therapeutics' Other Operating Expenses stood at $742000.0 in 2021, then soared by 151.75% to $1.9 million in 2022, then fell by 20.45% to $1.5 million in 2023, then decreased by 10.43% to $1.3 million in 2024, then increased by 11.5% to $1.5 million in 2025.
  • The last three reported values for Other Operating Expenses were $1.5 million (Q4 2025), $2.1 million (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.